What is the price of Medigene AG (MDG1)

The price of Medigene AG (MDG1) is $0.14942078

What is the market cap of Medigene AG (MDG1)

The market cap of Medigene AG (MDG1) is $3.86M

Medigene AG (MDG1) EPS

Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.

Year	EPS	Change
2026 (TTM)	$-0.96	-34.55%
2023	$-1.46	112.56%
2022	$-0.69	-21.60%
2021	$-0.88	-67.76%
2020	$-2.72	57.18%
2019	$-1.73	76.89%
2018	$-0.98	35.69%
2017	$-0.72	52.04%
2016	$-0.47	-43.37%
2015	$-0.84	47.02%
2014	$-0.57	-61.35%
2013	$-1.47	-30.29%
2012	$-2.11	-226.39%
2011	$1.67	-133.67%
2010	$-4.96	-28.97%
2009	$-6.98	-27.17%
2008	$-9.59	-8.89%
2007	$-10.52	243.28%
2006	$-3.07	-47.37%
2005	$-5.83	-37.47%
2004	$-9.32	0.00%

Year

EPS

Change

2026 (TTM)

$-0.96

-34.55%

2023

$-1.46

112.56%

2022

$-0.69

-21.60%

2021

$-0.88

-67.76%

2020

$-2.72

57.18%

2019

$-1.73

76.89%

2018

$-0.98

35.69%

2017

$-0.72

52.04%

2016

$-0.47

-43.37%

2015

$-0.84

47.02%

2014

$-0.57

-61.35%

2013

$-1.47

-30.29%

2012

$-2.11

-226.39%

2011

$1.67

-133.67%

2010

$-4.96

-28.97%

2009

$-6.98

-27.17%

2008

$-9.59

-8.89%

2007

$-10.52

243.28%

2006

$-3.07

-47.37%

2005

$-5.83

-37.47%

2004

$-9.32

0.00%

Company	EPS	EPS Difference	Country
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-1,912.66%	US
Argenx SE ARGX.US	$27.74	-3,003.19%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$13.70	-1,533.81%	BE

Company

EPS

EPS Difference

Country